Press releases

20 April, 2017

Regulatory

NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects

Lund, Sweden, 20 April 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical results demonstrating anti-fibrotic effects with NV55 ...

5 April, 2017

Regulatory

NeuroVive’s lead NASH project to be presented at The International Liver Congress™

Lund, Sweden, April 5, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that an abstract with preclinical data related to t ...

31 March, 2017

Regulatory

Number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, March 31, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in N ...

23 March, 2017

Regulatory

NeuroVive Pharmaceutical AB publishes 2016 Annual report

Lund, Sweden, March 23, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the English version of the Annual report for ...

23 March, 2017

Regulatory

Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB

The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, April 27, 2017, at 4 pm at Medicon Village, Scheelev ...

22 February, 2017

Regulatory

NeuroVive appoints recognized scientific advisors and enters research agreements in NASH and hepatocellular carcinoma

Lund, Sweden, February 22, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced two new research agreements and the appointment ...

21 February, 2017

Regulatory

NeuroVive Pharmaceutical AB Year End Report January – December 2016

Important steps forward and new research collaborations

2 February, 2017

Regulatory

NeuroVive’s new generation of sanglifehrin-based compounds demonstrate potent inhibitory effects on human hepatocellular cancer cells

Lund, Sweden, February 2, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, presents preclinical data from a new generation of sanglifehrin- ...

25 January, 2017

Regulatory

NeuroVive redirects research resources from Asian subsidiary to parent

Lund, Sweden, January 25, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that its Taiwan-based subsidiary's research reso ...

23 January, 2017

Regulatory

NeuroVive signs mitochondrial medicine research agreement with US key opinion leader

Lund, Sweden, January 23, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announces that NeuroVive has signed a preclinical collaboration agreement with the Children's ...

19 January, 2017

Regulatory

NeuroVive presents positive preclinical data in hepatocellular cancer at HCC Summit

Lund, Sweden, January 19, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that an abstract with novel preclinical cancer d ...

10 January, 2017

Regulatory

NeuroVive signs collaboration agreement with Karolinska Institutet

Lund, Sweden, January 10, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that a collaboration agreement has been signed w ...